Cabaletta Bio, Inc. (NASDAQ:CABA) Receives $30.11 Average PT from Brokerages

Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) have been given an average rating of “Buy” by the nine ratings firms that are presently covering the stock, MarketBeat reports. Nine investment analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $30.11.

A number of brokerages recently issued reports on CABA. Cantor Fitzgerald restated an “overweight” rating and issued a $50.00 target price on shares of Cabaletta Bio in a report on Friday, June 21st. Stifel Nicolaus reissued a “buy” rating and issued a $32.00 price target on shares of Cabaletta Bio in a research note on Monday, June 17th. Wells Fargo & Company cut their price objective on Cabaletta Bio from $35.00 to $20.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Cabaletta Bio in a research report on Tuesday, September 17th. Finally, Evercore ISI reduced their price target on shares of Cabaletta Bio from $25.00 to $15.00 and set an “outperform” rating for the company in a research report on Monday, August 12th.

Institutional Investors Weigh In On Cabaletta Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System grew its holdings in shares of Cabaletta Bio by 6.0% during the 1st quarter. California State Teachers Retirement System now owns 30,428 shares of the company’s stock valued at $519,000 after acquiring an additional 1,711 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Cabaletta Bio by 65.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 8,206 shares of the company’s stock valued at $140,000 after purchasing an additional 3,244 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Cabaletta Bio by 8.0% during the second quarter. The Manufacturers Life Insurance Company now owns 56,424 shares of the company’s stock valued at $422,000 after purchasing an additional 4,191 shares during the last quarter. AlphaCentric Advisors LLC grew its stake in Cabaletta Bio by 7.7% in the second quarter. AlphaCentric Advisors LLC now owns 70,000 shares of the company’s stock valued at $524,000 after purchasing an additional 5,000 shares in the last quarter. Finally, TD Asset Management Inc increased its position in Cabaletta Bio by 5.5% in the 2nd quarter. TD Asset Management Inc now owns 134,030 shares of the company’s stock worth $1,003,000 after purchasing an additional 7,000 shares during the last quarter.

Cabaletta Bio Stock Performance

NASDAQ:CABA opened at $4.70 on Friday. The company has a 50-day moving average of $5.62 and a 200-day moving average of $10.42. The firm has a market cap of $226.90 million, a price-to-earnings ratio of -2.75 and a beta of 2.40. Cabaletta Bio has a twelve month low of $3.47 and a twelve month high of $26.35.

Cabaletta Bio (NASDAQ:CABA) last issued its earnings results on Thursday, August 8th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.01). On average, research analysts forecast that Cabaletta Bio will post -2.21 earnings per share for the current year.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.